Skip to content
DataLookout
Menu

NCT04060017

Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jul 31, 2026 to Jan 31, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 13 of 13 entries
    • Site details revised at 1 of 2 sites
    • Publications: details revised at 5 of 5 entries
  2. Notable Primary and study completion dates pushed to Jul 31, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v11
  3. Notable Primary completion date: Jan 2025 to Dec 2025
    • Study completion date: Jan 2025 to Jun 2026
    v10
  4. Minor Site contacts updated at 2 of 2 sitesv9
  5. Notable Lead sponsor: Rossignol Medical Center to Southwest Autism Research & Resource Centerv8 Show 4 more changesShow less
    • Trial status: Active, Not Recruiting to Recruiting
    • Secondary endpoints: 14 to 13
    • Site details revised at 2 of 2 sites
    • Collaborators: 3 to 2
Show 6 earlier versionsHide 6 earlier versions
  1. Notable Primary and study completion dates: Jan 2023 to Jan 2025v7
  2. Notable Trial status: Suspended to Active, Not Recruiting
    • Study sites revised (2)
    v6
  3. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Pending New IRB Approvalv5 Show 6 more changesShow less
    • Lead sponsor: Phoenix Children's Hospital to Rossignol Medical Center
    • Eligibility criteria expanded, about 23 words
    • Primary and study completion dates: Dec 2022 to Jan 2023
    • Secondary endpoints revised (14)
    • Study sites revised (2)
    • Collaborators: 4 to 3
  4. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Eligibility criteria expanded, about 103 words
    • Start date changed from estimate of Oct 1, 2020 to Sep 22, 2020
    • Secondary endpoints: 13 to 14
    • Site details revised at 2 of 2 sites
  5. Notable Primary and study completion dates: Dec 2021 to Dec 2022
    • Start date: May 2020 to Oct 1, 2020
    v3
  6. Notable Start date: Dec 2019 to May 2020v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Evaluate the change in measures of expressive language
Timeframe: Screening, Week 12, Week 24

Secondary (12)

Evaluate the change in measures of receptive language
Evaluate the safety and tolerability of L-leucovorin calcium in young children with ASD
Evaluate the safety of L-leucovorin calcium in young children with ASD
Evaluate the safety of L-leucovorin calcium in young children with ASD on antiepileptic drugs
Evaluate the overall change in core autism symptoms of social communication
Show 7 moreShow less
Evaluate the change in stereotypical autism symptoms
Evaluate the change in social withdrawal autism symptoms
Evaluate the change in effects of autism symptoms most problematic to family members
Evaluate change in overall autism severity
Evaluate change in autism severity of specific symptoms
Evaluate the change in overall cognitive ability
Evaluate the change in adaptive functioning

Arms and interventions

L-leucovorin calciumExperimental

The liquid form of leucovorin calcium will be dosed by weight, with a target dose of 1mg/kg/day, divided into two daily doses. This product may be taken alone or mixed with liquid. Participants randomized to this arm will receive active treatment for both 12-week phases of the study.

PlaceboPlacebo comparator

The placebo will mimic the experimental treatment in flavor, odor, packaging, and dosing instructions. Participants randomized to this arm will receive placebo for the first 12 weeks of the study, then active treatment for the remaining 12 weeks.

Drugs: Levoleucovorin Calcium

Other: Placebo

Sites

2 sites in 1 country